Results 231 to 240 of about 490,106 (356)

Complement 5a (C5a), complement 5a receptor (C5aR; CD88), complement 5a–like receptor (C5L2) [PDF]

Science-Business eXchange, 2008
openaire   +1 more source

Blockade of the Complement C5a Receptor Reduces Incisional Allodynia, Edema, and Cytokine Expression [PDF]

, 2006
J. David Clark, Yanli Qiao, Xiangqi Li, Xiaoyou Shi, Martin S. Angst, David C. Yeomans   +5 more
openalex   +1 more source

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Complement Receptor 1 Enhancement in Recurrent Membranous Nephropathy Following Kidney Transplantation: A Case Report. [PDF]

Kidney Med
Kounoue N, Oguchi H, Hashiguchi A, Honda K, Kang D, Mikami T, Tochigi N, Kawamura T, Itabashi Y, Yonekura T, Sakurabayashi K, Sakai K.   +11 more
europepmc   +1 more source

Complement receptor 3 mediates Aspergillus fumigatus internalization into alveolar epithelial cells with the increase of intracellular phosphatidic acid by activating FAK. [PDF]

Virulence, 2021
Han X, Su X, Li Z, Liu Y, Wang S, Zhu M, Zhang C, Yang F, Zhao J, Li X, Chen F, Han L.   +11 more
europepmc   +1 more source

Structural insight on the recognition of surface-bound opsonins by the integrin aI-domain of complement receptor 3

, 2013
Goran Bajic, Laure Yatime, Vorup-Jensen Thomas, Andersen Gregers   +3 more
openalex   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Toxin protein LukS-PV targeting complement receptor C5aR1 inhibits cell proliferation in hepatocellular carcinoma via the HDAC7-Wnt/β-catenin axis. [PDF]

J Biol Chem
Shi L, Zhang S, Liu G, Nie Z, Ding P, Chang W, Dai Y, Ma X.   +7 more
europepmc   +1 more source

Elementary immunology [PDF]

, 2017
Gogolák, Péter, Koncz, Gábor
core  

The McCance Brain Care Score and Mortality: Evidence From a Large‐Scale Population‐Based Cohort

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives This study aimed to examine the relationship between the McCance Brain Care Score (BCS) and mortality in the general population. Methods We conducted a prospective, population‐based cohort study using data from the UK Biobank. Participants with complete data enabling calculation of BCS and full mortality information were included ...
Zhiqiang Xu, Xiaoxiao Wang, Nan Li
wiley   +1 more source